InfuSystem Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InfuSystem in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" InfuSystem stock.
View analyst ratings for InfuSystem or view top-rated stocks.

Wall Street analysts have given InfuSystem a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InfuSystem wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

InfuSystem is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for InfuSystem.

InfuSystem Holdings Inc. (NYSEAMERICAN:INFU) announced its quarterly earnings results on Thursday, May, 6th. The medical instruments supplier reported $0.03 EPS for the quarter, missing the Zacks' consensus estimate of $0.04 by $0.01. The medical instruments supplier had revenue of $24.46 million for the quarter, compared to analysts' expectations of $24.50 million. InfuSystem had a trailing twelve-month return on equity of 52.87% and a net margin of 18.36%.
View InfuSystem's earnings history.

InfuSystem issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $107 million-$110 million, compared to the consensus revenue estimate of $108.97 million.

3 brokers have issued 12-month price objectives for InfuSystem's stock. Their forecasts range from $26.00 to $28.00. On average, they expect InfuSystem's share price to reach $27.00 in the next year. This suggests a possible upside of 40.2% from the stock's current price.
View analysts' price targets for InfuSystem or view top-rated stocks among Wall Street analysts.

Some companies that are related to InfuSystem include Pulmonx (LUNG), Alphatec (ATEC), Treace Medical Concepts (TMCI), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), OrthoPediatrics (KIDS), CryoLife (CRY), Atrion (ATRI), SI-BONE (SIBN), Tactile Systems Technology (TCMD), Bioventus (BVS), Cerus (CERS), AngioDynamics (ANGO), Orthofix Medical (OFIX) and Asensus Surgical (ASXC).
View all of INFU's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InfuSystem investors own include Macquarie Infrastructure (MIC), Ampio Pharmaceuticals (AMPE), Second Sight Medical Products (EYES), Navidea Biopharmaceuticals (NAVB), Otelco (OTEL), Pershing Gold (PGLC), Palatin Technologies (PTN), AgroFresh Solutions (AGFS), Advanced Micro Devices (AMD) and Digital Turbine (APPS).

InfuSystem trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "INFU."

InfuSystem's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Minerva Advisors LLC (4.38%), BlackRock Inc. (3.99%), Russell Investments Group Ltd. (3.26%), Renaissance Technologies LLC (2.63%), Punch & Associates Investment Management Inc. (2.17%) and Kennedy Capital Management Inc. (1.38%). Company insiders that own InfuSystem stock include Awm Investment Company, Inc, Barry G Steele, Blueline Capital Partners Ii,, Carrie Lachance, Christopher R Sansone, Gregg Owen Lehman, Jeannine Sheehan, Meridian Ohc Partners, Lp, Paul Andrew Gendron, Richard Dilorio, Scott Shuda and Thomas Mark Ruiz.
View institutional ownership trends for InfuSystem.

INFU stock was sold by a variety of institutional investors in the last quarter, including Minerva Advisors LLC, Wedge Capital Management L L P NC, EAM Investors LLC, Renaissance Technologies LLC, Friess Associates LLC, EAM Global Investors LLC, Northern Trust Corp, and Millennium Management LLC. Company insiders that have sold InfuSystem company stock in the last year include Blueline Capital Partners Ii,, Gregg Owen Lehman, Meridian Ohc Partners, Lp, Richard Dilorio, and Thomas Mark Ruiz.
View insider buying and selling activity for InfuSystem or view top insider-selling stocks.

INFU stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Goldman Sachs Group Inc., Calamos Advisors LLC, Kennedy Capital Management Inc., Acuitas Investments LLC, Sowell Financial Services LLC, Dimensional Fund Advisors LP, and Geode Capital Management LLC. Company insiders that have bought InfuSystem stock in the last two years include Awm Investment Company, Inc, Barry G Steele, Carrie Lachance, Christopher R Sansone, Jeannine Sheehan, Paul Andrew Gendron, Richard Dilorio, and Scott Shuda.
View insider buying and selling activity for InfuSystem or or view top insider-buying stocks.

Shares of INFU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INFU stock can currently be purchased for approximately $19.26.

InfuSystem has a market capitalization of $394.23 million and generates $97.39 million in revenue each year. The medical instruments supplier earns $17.33 million in net income (profit) each year or $0.80 on an earnings per share basis.

InfuSystem employs 282 workers across the globe.

The official website for InfuSystem is ir.infusystem.com.

InfuSystem is headquartered at 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States.

InfuSystem's mailing address is 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States. The medical instruments supplier can be reached via phone at +1-248-2911210.